check_circleStudy Completed
Atopic Dermatitis, Eczema
Bayer Identifier:
15446
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
HPA Axis Study in Adults
Trial purpose
A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in adults with atopic dermatitis.
Key Participants Requirements
Sex
BothAge
18 - N/ATrial summary
Enrollment Goal
23Trial Dates
July 2011 - December 2011Phase
Phase 2Could I Receive a placebo
NoProducts
Mapracorat (BAY86-5319)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | PAREXEL Bloemfontein | Bloemfontein, South Africa |
Completed | PAREXEL George | George, South Africa |
Completed | PAREXEL Port Elizabeth | Port Elizabeth, South Africa |
Primary Outcome
- HPA axis response to Cosyntropin: Number of subjects with adrenal suppressiondate_rangeTime Frame:measured after 4 weeks of therapyenhanced_encryptionYesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
N/ABlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
1